Subsequent testing revealed that tazarotene in combination with another retinoic acid derivative, bexarotene, partially but significantly restored different lysosomal and nonlysosomal sulfatase activities in MSD patient‐derived fibroblasts, independent of the disease‐causing SUMF1 mutation. The gene discussed is SUMF1; the disease is Multiple sulfatase deficiency.